The Clinical Analysis Of 21-gene Recurrence Score In Early-stage Breast Cancer

ObjectiveTo explore the correlation of 21-gene recurrence score assay with the clinicopathological characteristics and the guidance in the treatment of in early-stage breast cancer. Methods This study enrolled 47 early breast cancer patients who underwent 21-gene recurrence score assay in our hospital from December 2012 to May 2015,and their clinicopathological data were analyzed.According to their recurrence score,they were classified into low recurrence risk group (4 cases,8.5%); Moderate risk group (20 cases,42.6%)and high risk group (23 cases,48.9%).Count data were compared with x2 test, Fisher’s exact test and continuity correction.Logistic regression was used for multivariate analysis. Results There was a significant difference in the tumor diameter (P=0.013).There was no significant difference in the Age,PR and Ki-67 protein expression(P=0.331、0.115、0.143).Multivariate analysis showed that diameter, Ki-67 protein expression and Age were independent influencing factors for RS(P <0.001、P<0.001, P=0.002).Among all the patients,28 patients(59.6%,28/47)received postoperative adjuvant chemotherapy,including 6 cases (30%,6/20) in moderate risk group and 22 cases(95.7%,22/23) in high risk group. The median follow-up time was 16 months. No case had recurrence and no distal metastasis or death was reported. Conclusion The 21-gene recurrence score is closely related to the clinicopathological characteristics of the patients with early breast cancer, including tumor diameter,Ki67,etc.